Vitti Labs Announces FDA Approval of Phase II IND Clinical Trial of Combination Mesenchymal Stem Cell and Exosome Treatment of Pulmonary Fibrosis Secondary to Novel Corona Virus Infection (COVID-19)
![FDA Approved sign](https://nationalstemcelltherapy.com/wp-content/uploads/2022/05/FDA-approved-sign.jpg)
LIBERTY, Mo., May 2, 2022 /PRNewswire/ — Vitti Labs, an AATB Accredited Tissue Bank focused on life Science Research, development, and manufacturing, announced today that the U.S. Food and Drug Administration (FDA) has approved their Investigational New Drug Application (IND) to move forward with Phase II Outpatient Clinical Trial using a combination of Umbilical Cord […]
FDA Approves Direct Biologics to Proceed with a Landmark Phase 3 Acute Respiratory Distress Syndrome (ARDS) Trial
![Direct Biologics logo](https://nationalstemcelltherapy.com/wp-content/uploads/2022/04/Direct_biologics_Logo.jpg)
AUSTIN, Texas, April 26, 2022 /PRNewswire/ — Direct Biologics, a regenerative biotechnology company with a groundbreaking extracellular vesicle (EV) platform technology, announced today that the FDA has approved the company to proceed with its Phase 3 clinical trial using its investigational EV drug, ExoFlo, to treat Acute Respiratory Distress Syndrome (ARDS) due to Covid-19. Direct […]